Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity ; volume:12 ; number:1 ; day:26 ; month:10 ; year:2022 ; pages:1-11 ; date:12.2022
Scientific reports ; 12, Heft 1 (26.10.2022), 1-11, 12.2022
- Creator
-
Zhong, Zhenwei
Zhang, Mengyao
Ning, Yanan
Mao, Guanchao
Li, Xiaopei
Deng, Qi
Chen, Xiaorui
Zuo, Dongliang
Zhao, Xiangyu
Xie, Ermin
Wang, Huajing
Guo, Lina
Li, Bohua
Xiao, Kai
He, Xiaowen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-22975-7
- URN
-
urn:nbn:de:101:1-2023011121203781276745
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhong, Zhenwei
- Zhang, Mengyao
- Ning, Yanan
- Mao, Guanchao
- Li, Xiaopei
- Deng, Qi
- Chen, Xiaorui
- Zuo, Dongliang
- Zhao, Xiangyu
- Xie, Ermin
- Wang, Huajing
- Guo, Lina
- Li, Bohua
- Xiao, Kai
- He, Xiaowen
- SpringerLink (Online service)
Other Objects (12)
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody
Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody
Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody